相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis
Yu Zhou et al.
IMMUNOTHERAPY (2023)
Influence of lung cancer model characteristics on tumor targeting behavior of nanodrugs
Weixia Xu et al.
JOURNAL OF CONTROLLED RELEASE (2023)
Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma
Alexandre Detappe et al.
NATURE NANOTECHNOLOGY (2023)
Thermal immuno-nanomedicine in cancer
Zhe Yang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2023)
Advances in Drug Delivery Systems Based on Red Blood Cells and Their Membrane-Derived Nanoparticles e
Phuong Hoang Diem Nguyen et al.
ACS NANO (2023)
Slimming and Reinvigorating Tumor-Associated Dendritic Cells with Hierarchical Lipid Rewiring Nanoparticles
Chunchen Xu et al.
ADVANCED MATERIALS (2023)
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Chong Kin Liam et al.
CLINICAL CANCER RESEARCH (2023)
Targeting drugs to tumours using cell membrane-coated nanoparticles
Ronnie H. Fang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2023)
Lung cancer immunotherapy: progress, pitfalls, and promises
Aritraa Lahiri et al.
MOLECULAR CANCER (2023)
An engineered influenza virus to deliver antigens for lung cancer vaccination
Dezhong Ji et al.
NATURE BIOTECHNOLOGY (2023)
Rare molecular subtypes of lung cancer
Guilherme Harada et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2023)
Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management
Josep M. Argiles et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2023)
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties
Huaxin Song et al.
SCIENCE TRANSLATIONAL MEDICINE (2023)
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Juliann Chmielecki et al.
NATURE COMMUNICATIONS (2023)
Approved Nanomedicine against Diseases
Yuanchao Jia et al.
PHARMACEUTICS (2023)
Supramolecular Theranostic Nanomedicine for In Situ Self-Boosting Cancer Photochemotherapy
Dan Wu et al.
BIOMACROMOLECULES (2023)
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
Mengshu You et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)
Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K/AKT and VEGF-MEK1/2/ERK1/2 signaling
Hong-jin Wang et al.
ACTA PHARMACOLOGICA SINICA (2022)
Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy
Michael P. Vincent et al.
CANCER CELL (2022)
FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway
Shike Yan et al.
FRONTIERS IN PHARMACOLOGY (2022)
The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment
Yingli Guo et al.
FRONTIERS IN IMMUNOLOGY (2022)
Polymeric nanocarriers: A promising tool for early diagnosis and efficient treatment of colorectal cancer
Mohamed Haider et al.
JOURNAL OF ADVANCED RESEARCH (2022)
Targeted Drug/Gene/Photodynamic Therapy via a Stimuli-Responsive Dendritic-Polymer-Based Nanococktail for Treatment of EGFR-TKI-Resistant Non-Small-Cell Lung Cancer
Jinxing Huang et al.
ADVANCED MATERIALS (2022)
Protein-Mimicking Nanoparticles in Biosystems
Xiaoyuan Ji et al.
ADVANCED MATERIALS (2022)
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Mayumi Ikeda-Imafuku et al.
JOURNAL OF CONTROLLED RELEASE (2022)
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
Melissa Johnson et al.
LUNG CANCER (2022)
Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges
Devaraj Ezhilarasan et al.
NANOMEDICINE (2022)
Therapeutic potential of human serum albumin nanoparticles encapsulated actinonin in murine model of lung adenocarcinoma
Priyanca Ahlawat et al.
DRUG DELIVERY (2022)
Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
Marco de Scordilli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer
Yujuan Duan et al.
FRONTIERS IN ONCOLOGY (2022)
Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery
Natalie Boehnke et al.
SCIENCE (2022)
Precisely Targeted Nano-Controller of PD-L1 Level for Non-Small Cell Lung Cancer Spinal Metastasis Immunotherapy
Lei Zhou et al.
ADVANCED HEALTHCARE MATERIALS (2022)
Bioavailability of nanomaterials: bridging the gap between nanostructures and their bioactivity
Mingjing Cao et al.
NATIONAL SCIENCE REVIEW (2022)
HSP70-Promoter-Driven CRISPR/Cas9 System Activated by Reactive Oxygen Species for Multifaceted Anticancer Immune Response and Potentiated Immunotherapy
Liang Zhao et al.
ACS NANO (2022)
Engineering Poly(ethylene glycol) Nanoparticles for Accelerated Blood Clearance Inhibition and Targeted Drug Delivery
Yuan Tian et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)
The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/ AKT/mTOR pathway
Qiuling Chen et al.
TRANSLATIONAL ONCOLOGY (2022)
Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)
Hong-Shuai Li et al.
CANCERS (2022)
A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models
Sang-Soo Kim et al.
CELLS (2022)
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Zhenyi Niu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment
Yueshui Zhao et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2022)
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer
Baolin Liu et al.
NATURE CANCER (2022)
Nanomaterials multifunctional behavior for enlightened cancer therapeutics
Ganji Seeta Rama Raju et al.
SEMINARS IN CANCER BIOLOGY (2021)
Nanoscale drug delivery systems for controllable drug behaviors by multi-stage barrier penetration
Jinjin Wang et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer- a drug development perspective
Julia Lai-Kwon et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The ancillary effects of nanoparticles and their implications for nanomedicine
Evan P. Stater et al.
NATURE NANOTECHNOLOGY (2021)
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Ying Jing et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer
Zhefeng Li et al.
NUCLEIC ACID THERAPEUTICS (2021)
MICAL2PV suppresses the formation of tunneling nanotubes and modulates mitochondrial trafficking
Fei Wang et al.
EMBO REPORTS (2021)
Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives
Keywan Mortezaee
LIFE SCIENCES (2021)
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer
Zhenchuan Liu et al.
MOLECULAR CANCER (2021)
Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells
Hua-Zhen Xu et al.
JOURNAL OF NANOBIOTECHNOLOGY (2021)
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Heidie Frisco Cabanos et al.
CANCERS (2021)
CoFe2O4-Quantum Dots for Synergistic Photothermal/Photodynamic Therapy of Non-small-Cell Lung Cancer Via Triggering Apoptosis by Regulating PI3K/AKT Pathway
Jingfeng Liu et al.
NANOSCALE RESEARCH LETTERS (2021)
Overcoming therapy resistance in EGFR-mutant lung cancer
Antonio Passaro et al.
NATURE CANCER (2021)
A Review of the Contribution of Mast Cells in Wound Healing: Involved Molecular and Cellular Mechanisms
Daniel Elieh Ali Komi et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2020)
Precision Management of Advanced Non-Small Cell Lung Cancer
Ching-Yao Yang et al.
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Novel molecular targets for the treatment of lung cancer
Rafael Rosell et al.
CURRENT OPINION IN ONCOLOGY (2020)
Folate receptor-targeted RNAi nanoparticles for silencing STAT3 in tumor-associated macrophages and tumor cells
Jing Chen et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2020)
Poly(1-vinylimidazole) polyplexes as novel therapeutic gene carriers for lung cancer therapy
Gayathri Kandasamy et al.
BEILSTEIN JOURNAL OF NANOTECHNOLOGY (2020)
Delivery strategies for macromolecular drugs in cancer therapy
Qin Guo et al.
ACTA PHARMACEUTICA SINICA B (2020)
Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)
Aaron C. Tan
THORACIC CANCER (2020)
Nano-manganese oxide-functionalized-oleyl amine as a simple and low cost nanosorbent for remediation of ZnII/CoII and their radioactive nuclides 65Zn and 60Co from water
Mohamed E. Mahmoud et al.
APPLIED RADIATION AND ISOTOPES (2020)
Memory T cells: strategies for optimizing tumor immunotherapy
Qingjun Liu et al.
PROTEIN & CELL (2020)
Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review
Mohamed Haider et al.
PHARMACEUTICS (2020)
Correlation Between Tumor-Associated Macrophage and Immune Checkpoint Molecule Expression and Its Prognostic Significance in Cutaneous Melanoma
Young Jae Kim et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Six Birds with One Stone: Versatile Nanoporphyrin for Single-Laser-Triggered Synergistic Phototheranostics and Robust Immune Activation
Yue Sun et al.
ADVANCED MATERIALS (2020)
Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling
Song Chen et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy
Nour Shobaki et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
Xin Cui et al.
ELIFE (2020)
Smart nanocarriers for cancer treatment: Clinical impact and safety
Zehuan Liao et al.
NANOIMPACT (2020)
Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients
Ilseon Hwang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells
Silke Eisinger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
Man Zhang et al.
NATURE COMMUNICATIONS (2020)
PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
Zhiyuan Zhu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
Dong Ha Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Graphene quantum dots (GQDs)-based nanomaterials for improving photodynamic therapy in cancer treatment
Hua-yang Fan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Smart cancer nanomedicine
Roy van der Meel et al.
NATURE NANOTECHNOLOGY (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
Dnyaneshwar Kalyane et al.
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition
Na Kong et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Antimicrobial Amino-Functionalized Nitrogen-Doped Graphene Quantum Dots for Eliminating Multidrug-Resistant Species in Dual-Modality Photodynamic Therapy and Bioimaging under Two-Photon Excitation
Wen-Shuo Kuo et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
Biocompatible Semiconductor Quantum Dots as Cancer Imaging Agents
Kevin J. McHugh et al.
ADVANCED MATERIALS (2018)
Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates
Hadeer M. Abdelaziz et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling
Mohammad Rasheduzzaman et al.
LIFE SCIENCES (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment
Ruixiang Li et al.
ACTA PHARMACEUTICA SINICA B (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
TECHNOLOGY FEATURE MOUSE MODELS WITH A HUMAN TOUCH
Mike May
NATURE (2018)
Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra et al.
JOURNAL OF NANOBIOTECHNOLOGY (2018)
Targeting Tumor Microenvironment by Bioreduction-Activated Nanoparticles for Light-Triggered Virotherapy
S. -Ja Tseng et al.
ACS NANO (2018)
The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes
Stefano Palazzoloa et al.
CURRENT MEDICINAL CHEMISTRY (2018)
A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions
Tony Eight Lin et al.
FRONTIERS IN PHARMACOLOGY (2018)
Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway
Donglai Chen et al.
FRONTIERS IN PHARMACOLOGY (2018)
A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer
Weidong Han et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2018)
Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
Wolfram C. M. Dempke et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Preparation and characterization of lipid nanoparticle/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells
Mustafa Kotmakci et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles
Gijung Kwak et al.
JOURNAL OF CONTROLLED RELEASE (2017)
CRH promotes human colon cancer cell proliferation via IL-6/JAK2/STAT3 signaling pathway and VEGF-induced tumor angiogenesis
Xianjun Fang et al.
MOLECULAR CARCINOGENESIS (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment
Chun Li et al.
BIOMATERIALS SCIENCE (2017)
Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles
Myung Goo Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells
Fengqiao Li et al.
AAPS JOURNAL (2017)
Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy
Yoshihiro Komohara et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases
M. Thorn et al.
CANCER GENE THERAPY (2016)
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
Vivek Asati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment
Yan Cui et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
Shiyong Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Targeted Therapy and Immunotherapy for Lung Cancer
Evan C. Naylor et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2016)
MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway
Po-Ming Chen et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles
Corey J. Bishop et al.
JOURNAL OF CONTROLLED RELEASE (2015)
The Evolution of Therapies in Non-Small Cell Lung Cancer
Vishal Boolell et al.
CANCERS (2015)
The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy
Simone Muenst et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Ludovica Ciuffreda et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Self-Assembly of Poly-Adenine-Tailed CpG Oligonucleotide-Gold Nanoparticle Nanoconjugates with Immunostimulatory Activity
Nan Chen et al.
SMALL (2014)
A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro
Cui-yan Han et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2013)
Progress in microRNA delivery
Yu Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Personalizing Therapy in Advanced Non-Small Cell Lung Cancer
Liza C. Villaruz et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
O. Arrieta et al.
BRITISH JOURNAL OF CANCER (2012)
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non-Small-Cell Lung Cancer
Vassiliki Papadimitrakopoulou
JOURNAL OF THORACIC ONCOLOGY (2012)
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
Michela Garofalo et al.
NATURE MEDICINE (2012)
STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo
Aws Alshamsan et al.
TRANSLATIONAL ONCOLOGY (2011)
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies
Paul K. Paik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer
Miao Zhong et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2010)
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches
Stephen Y. Lai et al.
DRUG RESISTANCE UPDATES (2010)
Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo
Shuxian Song et al.
FASEB JOURNAL (2009)
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
Marcin Kortylewski et al.
NATURE BIOTECHNOLOGY (2009)
Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo
Shuxian Song et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
J. A. McCubrey et al.
LEUKEMIA (2008)
Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2008)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Absence of JAK2 V617F mutation in gastric cancers
JW Lee et al.
ACTA ONCOLOGICA (2006)
Cancer nanotechnology: Opportunities and challenges
M Ferrari
NATURE REVIEWS CANCER (2005)
Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation
CS Shi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells
A Aicher et al.
NATURE MEDICINE (2003)